There isn't anything nefarious about conducting an independent review of the trial results. Most companies do this internally (if they have the expertise and regardless of the "success" or "failure" of the trial). The investigators in the intital trial are only asked to report on the endpoints for that trial. Some companies commission the review work to be done by others who have the capability to do it and can provide an independent view. It really is normal practice and I doubt the post-study review of the results requires an announcement to the market. Clearly, an outcome of the review such as this does require an announcement.
The trades prior to the recent announcement might look a little "off". That is another issue. Coincidence or not? I don't know. But, back on the post-study review - that is quite normal as there are lots of things to find in the data that the Investigators in the initial study weren't asked to look for. GLTA
BNO Price at posting:
19.5¢ Sentiment: Hold Disclosure: Held
